Intest Res.  2020 Jan;18(1):34-44. 10.5217/ir.2019.09147.

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases

• Park SH
• Park JC
• Lukas M
• Kolar M
• Loftus, Jr EV

• KMID: 2501365
• DOI: http://doi.org/10.5217/ir.2019.09147

Abstract

The inflammatory bowel diseases (IBD), which consist of Crohn’s disease and ulcerative colitis, are chronic, incurable immunemediated inflammatory disorders of the intestine. As IBD incidence continues to increase globally and its mortality is low, prevalent cases of IBD are rapidly increasing, thereby leading to a substantial increase in health care costs. Although the introduction of biologic agents for IBD management has revolutionized the armamentarium of IBD therapy, the high cost of this therapy is concerning. With the expirations of patents for existing biologic agents (originals), biosimilars with cheaper costs have been highlighted in the field of IBD. Despite concerns regarding their short- and long-term efficacy, safety, immunogenicity, and interchangeability, increasing evidence via prospective observations and phase III or IV clinical trials, which aim to prove the “biosimilarity” of biosimilars to originals, has partly confirmed their efficacy, safety, and interchangeability. Additionally, although patients and physicians are reluctant to use biosimilars, a positive budget impact has been reported owing to their use in different countries. In the near future, multiple biosimilars with lower costs, and efficacy and safety profile similar to originals, could be used to treat IBD; thus, further consideration and knowledge dissemination are warranted in this new era of biosimilars.

Keyword

Biosimilars; Inflammatory bowel diseases; Crohn disease; Colitis, ulcerative; Biologic factors

Reference

1. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2014; 63:1607–1616.

2. Park SH, Yang SK, Park SK, et al. Long-term prognosis of Crohn’s disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea. Inflamm Bowel Dis. 2014; 20:488–494.

3. Lee HS, Park SH, Yang SK, et al. Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea. J Crohns Colitis. 2015; 9:147–155.

4. Aniwan S, Park SH, Loftus EV Jr. Epidemiology, natural history, and risk stratification of Crohn’s disease. Gastroenterol Clin North Am. 2017; 46:463–480.

5. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142:46–54.

6. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008; 135:1907–1913.

7. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013; 58:519–525.

8. Marchetti M, Liberato NL. Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of modelbased analyses. Expert Rev Pharmacoecon Outcomes Res. 2014; 14:815–824.

9. Park DI. Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res. 2016; 14:15–20.

10. Declerck P, Mellstedt H, Danese S. Biosimilars: terms of use. Curr Med Res Opin. 2015; 31:2325–2330.

11. Guidance for industry: quality considerations in demonstrating biosimilarity to a therapeutic protein product to a reference product. US Food and Drug Administration Web site. https://www.fda.gov/downloads/drugs/guidances/ucm291134.pdf. Accessed Jan 12, 2020.

12. Müller-Ladner U, Hong S, Oh C, Taylor P. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe. Expert Rev Clin Immunol. 2015; 11 Suppl 1:S5–S14.

13. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013; 72:315–318.

14. Chang S, Hanauer S. Extrapolation and interchangeability of infliximab and adalimumab in inflammatory bowel disease. Curr Treat Options Gastroenterol. 2017; 15:53–70.

15. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012; 91:405–417.

16. FDA approves Inflectra, a biosimilar to Remicade. US Food and Drug Administration Web site. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm. Updated Apr 5, 2016. Accessed Jan 12, 2020.

17. Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013; 5:621–623.

18. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013; 72:1605–1612.

19. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, doubleblind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72:1613–1620.

20. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015; 30:1705–1712.

21. Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015; 60:951–956.

22. Park SH, Kim YH, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015; 9 Suppl 1:35–44.

23. Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015; 9 Suppl 1:45–52.

24. Gecse KB, Vegh Z, Kurti Z, et al. P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort. J Crohn Colitis. 2017; 11(Suppl 1):S246.

25. Guidi L, Fiorino G, Variola A, et al. OP005 The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across Italy. J Crohn Colitis. 2017; 11(Suppl 1):S3.

26. Farkas K, Rutka M, Golovics PA, et al. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis. 2016; 10:1273–1278.

27. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462–2476.

28. Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019; 393:1699–1707.

29. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017; 389:2304–2316.

30. Joergensen KK, Olsen IC, Goll GL, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn’s disease and ulcerative colitis from the nor-switch trial. Gastroenterology. 2017; 152(5 Suppl 1):S65–S66.

31. Kolar M, Duricova D, Bortlik M, et al. Infliximab biosimilar (Remsima™) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis. 2017; 35:91–100.

32. Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017; 11:690–696.

33. Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease: an update. J Crohns Colitis. 2017; 11:26–34.

34. AGA makes six recommendations to FDA on interchangeable biosimilars. American Gastroenterological Association Web site. http://www.gastro.org/news_items/aga-makes-six-recommendations-to-fda-on-interchangeable-biosimilars. Updated May 25, 2017. Accessed Jan 12, 2020.

35. Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015; 9:806–815.

36. O’Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014; 20:1–6.

37. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004; 350:876–885.

38. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541–1549.

39. Bálint A, Rutka M, Végh Z, et al. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Expert Opin Drug Saf. 2017; 16:885–890.

40. Gecse KB, Lovász BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016; 10:133–140.

41. Lovasz BD, Kurti Z, Rutka M, et al. DOP033. Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort. J Crohn Colitis. 2016; 10(Suppl 1):S46.

42. Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016; 65:1132–1138.

43. Smits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from Remicade^® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016; 10:1287–1293.

44. Smits LJT, Grelack A, Derikx LAAP, et al. Long-term clinical outcomes after switching from Remicade(^®) to biosimilar CTP13 in inflammatory bowel disease. Dig Dis Sci. 2017; 62:3117–3122.

45. Sieczkowska J, Jarzebicka D, Oracz G, et al. P617. Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn’s disease. J Crohn Colitis. 2016; 10(Suppl 1):S413–S414.

46. Strik AS, van de Vrie W, Megen Y, et al. Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent Crohn’s disease: a prospective study. Gastroenterology. 2017; 152(5 Suppl 1):S66.

47. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets. IMS Health Web site. https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf. Updated Jun 2016. Accessed Jan 12, 2020.

48. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis Organization. J Crohns Colitis. 2014; 8:1548–1550.

49. Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn’s Colitis Organization [ECCO] members: an updated survey. J Crohns Colitis. 2016; 10:1362–1365.

50. Dave CV, Kesselheim AS, Fox ER, Qiu P, Hartzema A. High generic drug prices and market competition: a retrospective cohort study. Ann Intern Med. 2017; 167:145–151.

51. Hirsch BR, Lyman GH. Will biosimilars gain momentum? J Natl Compr Canc Netw. 2013; 11:1291–1297.

52. Gulacsi L, Pentek M, Rencz F, et al. Biosimilars for the management of inflammatory bowel diseases: economic considerations. Curr Med Chem. 2019; 26:259–269.

53. Kanters TA, Stevanovic J, Huys I, Vulto AG, Simoens S. Adoption of biosimilar infliximab for rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases in the EU5: a budget impact analysis using a Delphi panel. Front Pharmacol. 2017; 8:322.

54. US doctors poised to prescribe biosimilars. GaBI Online -Generics and Biosimilars Initiative Web site http://www.gabionline.net/Biosimilars/General/US-doctors-poised-to-prescribe-biosimilars. Updated Mar 18, 2016. Accessed Jan 12,2020.

55. Brodszky V, Rencz F, Péntek M, Baji P, Lakatos PL, Gulácsi L. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016; 16:119–125.

56. Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima^®) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015; 32:742–756.

57. Khraishi M, Stead D, Lukas M, Scotte F, Schmid H. Biosimilars: a multidisciplinary perspective. Clin Ther. 2016; 38:1238–1249.

58. Rencz F, Gulácsi L, Péntek M, et al. Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017; 17:597–606.

59. Baji P, Gulácsi L, Brodszky V, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United European Gastroenterol J. 2018; 6:310–321.

60. Sullivan E, Piercy J, Waller J, Black CM, Kachroo S. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn’s disease across Germany. PLoS One. 2017; 12:e0175826.

61. Peyrin-Biroulet L, Lönnfors S, Roblin X, Danese S, Avedano L. Patient perspectives on biosimilars: a survey by the European Federation of Crohn’s and Ulcerative Colitis Associations. J Crohns Colitis. 2017; 11:128–133.

62. Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017; 14:22–31.

63. Biosimilar Product Information. US Food and Drug Administration Web site. https://www.fda.gov. Accessed Jan 12, 2020.

64. Medicines_Search_Biosimilar. European Medicines Agency Web site. https://www.ema.europa.eu. Accessed Jan 12, 2020.

65. Macaluso FS, Cappello M, Giuffrida E, et al. Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. Aliment Pharmacol Ther. 2019; 49:234–236.

66. Goncalves J, Myung G, Park M, Jeong D, Ghil J. SB5 shows crossimmunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therap Adv Gastroenterol. 2019; 12:1756284819891081.